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1. Introduction 
Crohn's disease (CD) and chronic ulcerative colitis (UC) are considered as two distinct forms 
of inflammatory bowel disease (IBD). In IBDs, the first clinical signs of disease begin typically 
between adolescence and the third decade of life (Andres & Friedman 1999; Baldassano & 
Piccoli 1999). CD is a non-specific granulomatous inflammatory disease affecting the lower 
end of the ileum and often involving the colon and other parts of the intestinal tract (Podolsky 
2002). CD was first reported by B. Crohn and his colleagues in 1932 and called Regional 
Enteritis (Matsuura et al. 1993). CD is diagnosed in four patients per 100 000 in the Northern 
Europe and the incidence and prevalence is rising (Elson et al. 1995). UC is a chronic disease of 
unknown etiology characterized by inflammation of the mucosa and sub-mucosa of the 
rectum (altimes) with a continuous extension to upper parts of the colon without healthy 
mucosa between inflammatory mucosa, which can be limited to the rectum (proctitis) to the 
colon below the lefts angle (left colitis), beyond the left angle (extensive colitis) or affect all the 
colon (pancolitis). UC is mostly characterized by bloody diarrhea. UC may have a prevalence 
of 100 case per 100 000 population in Northern Europe (Satsangi et al. 1996) 
The causes of CD and UC remain to be clarified. However, genetic factors in combination 
with environmental factors are suspected to be involved in the pathogenesis of Crohn's 
disease (Baker et al. 1981; Podolsky 2002). Inadequate or prolonged activation of the 
intestinal immune system plays an important role in the pathophysiology of chronic 
mucosal inflammation (Elson et al. 1995; Matsuura et al. 1993). 
CD and UC are characterized by periods of remission followed by episodes of clinical 
relapse, characterized by an increase in symptoms usually due to acute intestinal 
inflammation. Treatment is primarily aimed at reducing inflammation during relapse and 
secondarily at prolonging the time-spent remission. Conventionally both of these aims are 
governed by consideration of clinical symptoms rather than objective evidence of 
inflammatory activity. Gastroenterologists are often faced with the difficulty of 
differentiating patients with irritable bowel syndrome from those with organic intestinal 
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pathologies, in particular inflammatory bowel disease. Many symptoms are common to 
both conditions including abdominal pain, bloating, excessive flatus and altered bowel habit 
while other clinical features such as a predominance of diarrhea and rectal bleeding will 
increase the likelihood of organic disease. Although symptoms are a surprisingly good 
guide to a diagnosis, most clinicians proceed to and rely on laboratory tests to aid in the 
differential diagnosis. The two main forms of IBD are both characterized by an aberrant 
immune response of intestinal mucosa. The enormous complexity of pathophysiology 
mandates a systematic approach to identify the molecular events that cause and perpetuate 
these chronic, relapsing inflammatory disorders. The ability to quantitate the global 
expression profiles at the level of RNA using oligonucleotide microarrays has recently been 
applied to investigate transcriptional signatures present in CD peripheral blood and CD 
gastrointestinal tissue (Lawrance et al. 2001; Warner & Dieckgraefe 2002). These studies 
identified genes involved in inflammatory response generally up-regulated in IBD and 
showed that the gastrointestinal tissue transcriptome obtained from UC and CD patients 
were quite distinct, with gene sets identified that appear to distinguish UC from CD tissue. 
In contrast to biopsies, peripheral blood is a much more accessible tissue source to 
distinguish between UC and CD. Circulating peripheral blood mononuclear cells (PBMCs) 
are responsible for the comprehensive surveillance of the body for signs of infection and 
disease. PBMCs may therefore serve as a surrogate tissue for evaluation of disease induced 
gene expression as biomarker of disease status or severity (Rockett et al. 2004). 
 
CD patient PBMC Age Gender 
CD1 51 F
CD2 50 F
CD3 18 M
CD4 53 F
Control PBMC Age Gender 
C1 30 F
C2 44 M
C3 50 M
C4 24 F
C5 30 M
Biopsies Physiological state Age of donor Gender of donor 
CD5 Inflamed 23 F 
CD6ni Non inflamed 24 F 
CD6i Inflamed 24 F 
CD7 Inflamed 21 F 
CD8 Inflamed 31 F 
UC1 Inflamed 45 F 
UC2ni Non inflamed 20 F 
UC2i Inflamed 20 F 
IBS 1 Inflamed 28 M 
IBS 2 Inflamed 59 F 
C6 Non inflamed 55 M 
Table 1. Origin of PBMCs and biopsies. CD = Crohn's Disease patient; UC = Ulcerative 
colitis patient; IBS = Irritable Bowel Syndrome patient, C = Disease free individual. 
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We here explored expression profiles of PBMCs from four CD patients compared to age and 
gender matched healthy individuals. We monitored as well the expression profiles of 
biopsies obtained by endoscopy from five CD patients, three UC, two intestinal disorders 
functional and one disease free individual (Table 1). To study the transcriptome we used 
“Taqman Low Density Arrays” microfluidic cards (Applied Biosystems), based on the 
technology of real-time PCR and Taqman probes. Such strategy is particularly attractive due 
to the quality of measurements of gene expression, the simplicity of implementation and the 
384 wells format thus covering the whole family of G Protein-Coupled Receptor (GPCR) on 
one plate. In this project, we used cards dedicated to study the GPCR transcriptome and this 
in two configurations. Card #1 was designed in 2004 by professor J. Haiech (UMR 7200 
CNRS, Faculty of Pharmacy, Illkirch). This card contained 355 GPCR, 16 housekeeping 
genes and 10 genes belonging to various categories. Card #2, used for monitoring biopsies, 
is produced as it by Applied Biosystems (ref. 4365295). This second card, designed two years 
later, takes in account updates on GPCR's annotation; it contained 365 GPCR including 4 
olfactory GPCR, 14 housekeeping genes and 2 genes of various functions. These two cards 
have 352 genes in common, including 10 housekeeping genes with 30 genes specific to each 
card. 
2. Materials and methods 
2.1 Blood and tissues culture 
Healthy donors with no clinical history were selected for PBMCs and tissues studies. 
Patients blood and tissues were obtained from CD patients at the Gastroentetology units 
from Strasbourg and Caen Universities hospitals (France). This work was approved by an 
authorized ethics committee (CPP Nord Ouest 2, Amiens, France), and carried out according 
to international guidelines. A fragment of each tissue specimen (colon, ileum, small 
intestine) was used for histopathological studies. The other part was immediately frozen on 
solution D (Chomczynski and Sacchi 1987) and stored at -70°C. PBMCs from healthy donors 
were separated as previously described (Boyum 1968). 
Peripheral blood diluted in Ca2+ and Mg2+ free HBSS (CMF-HBSS) containing 100 IU 
heparin/ml was layered over Histopaque-1077 and centrifuged for 30 min at 400g (20°C). 
Cells harvested at the interface were washed 3 times in CMF-HBSS and resuspended at a 
final concentration of 5x105 cells/ml in RPMI 1640 supplemented by 10% heat-inactivated 
fetal bovin serum (FBS). PBMCs were seeded on 24-well culture plates at a final 
concentration of 5.105 cells/ml in RPMI-1640 supplemented with 10% heat-inactivated 
FBS (v/v) and penicillin–streptomycin (100g/ml). Control cells and CD patients cells 
were activated, or not, by LPS (5g/ml) for 2 hours 30 min at 37°C. PBMCs were 
centrifuged and the pellets were pooled, frozen in liquid nitrogen and kept at –80°C until 
testing. 
2.2 Flow cytometry 
Flow cytometry was performed on a Guava EasyCyte Plus System (Merck/Millipore/ 
Guava, Hayward, USA) equipped with a 488 nm laser that illuminates each cell then 
fluorescence is collected at different wavelength (530 ± 15 nm, 575 ± 13 nm and 660 ± 10 nm). 
The granularity, size, cell number/ml and fluorescence are recorded at a speed of 800 cells 
per second. 
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2.3 TNF- secretion tests 
Human PBMCs were incubated in 24 well culture plates in culture medium at 5x105 cells/ml 
for 24 h at 37°C in a humidified 5% CO2 / 95% air atmosphere in presence of increasing 
concentrations of the somatostatin analogues ranging from 10-7M to 10-5M, with or without 
activation by LPS (5g/ml). Compounds were dissolved in water. Control samples always 
contained the same amount of water (without compounds). For ELISA, plates were 
centrifuged after incubation for 15 min at 200xg (20°C). Supernatants were stored at -80°C 
until testing. For coating, human TNF- antibody 0,5mg/ml (BD Pharmingen, Le Pont de 
Claix, France) was diluted to 1/100 in Binding Solution (Na2HPO4 0,1M+NaH2PO4 0,1M à 
pH9) and added in the 96 wells plate (Nunc Maxisorp 96-wells, VWR, Val de Fontenay, 
France). The plate was sealed to prevent evaporation, and incubated overnight at 4°C. The 
96-wells plate was then washed once with PBS 1x/Tween 0,05% then saturated by addition 
of 200µl PBS/milk 5% during 2 hours at room temperature. After two washes with PBS 
1x/Tween 0,05%, PBMC supernatants were added. TNF- protein standard 1g/ml (BD 
Pharmingen, Le Pont de Claix, France) with dilutions (10000, 3333, 1111, 370, 123, 41 and 
5pg/ml) was added in corresponding standard wells for the statistic correlation. The 
detection was done with Human TNF- biotin 0,5mg/ml (BD Pharmingen, Le Pont de 
Claix, France) during one hour at room temperature. The plate was washed four times with 
PBS 1x/Tween 0,05%. Peroxydase/streptavidin 1,25 mg/ml (Zymed, In Vitrogen, Cergy 
Pontoise, France) was added and the plate incubated for one hour at room temperature. The 
plate was washed four times in PBS 1x/Tween 0,05%, and OPD (Sigma, Lyon, France) was 
used to determine the amount of TNF-detected in each well. The plate was then analysed 
in a spectrophotometer at 450nm (Molecular Devices, VersaMax Tunable Microplate Reader, 
Sunnyvale, USA). 
2.4 RNA Extraction of tissues and PBMCs 
The tissues were defrosted 15 minutes on ice (Chomczynski & Sacchi 1987). The cells were 
broken with a sterile piston, and put in sodium acetate 2M pH 4, phenol pH 4 saturated and 
chloriform/isoamylic alcool (49:1). After shaking, the membranes were incubated 15 
minutes on ice and centrifuged 20 minutes at 12000g at 4°C. Aqueous phase with the RNA 
were kept and precipitated with isopropanol one hour at -20°C. The RNA were centrifuged 
20 minutes 12000g at 4°C, and washed with 500µl of ethanol 70% stored at -20°C. They were 
centrifuged 5 minutes 12000g at 4°C and washed again three times. The RNA were dried 
with Speed Vac, and added with sterile water. RNA was isolated from PBMC cells pellet 
(5.106 cells) with Tri reagent (Molecular Research Center, Inc., Cincinnati, Ohio, USA) 
according to the manufacturer's instructions. 
Total mRNA were checked for integrity and concentration using the RNA 6000 LabChip kit 
on the Agilent 2100 bio analyzer (ratios of 28S RNA/18S RNA were above 1.6) and for 
purity by reading the absorbance at 260 and 280 nm (ratios A260/A280 were comprised 
between 1.8 and 2.0). 
2.5 Real-Time RT-PCR and PCR 
Five g of total RNA is reversely transcribed to single-stranded cDNA using the "High-
Capacity cDNA AUCive™ Kit" (Applied Biosystems, Foster City, California, USA). RNA is 
pre-incubated at 25ºC for 10 min, followed by 2 hours at 37ºC, according to the 
manufacturer’s recommendations (Applied Biosystems, Foster City, California, USA). 
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Subsequently, cDNA was kept at –20 °C until used. An aliquot of cDNA (850 ng) was mixed 
carefully in 850µL TaqMan Universal PCR Master Mix (PE Applied Biosystems).  On the 
card keeped at room temperature, 105µL of the sample were loaded into each of 8 ports on 
the TaqMan Low-Density Array (Applied Biosystems, Foster City, CA). The TaqMan Low-
Density Array microfluidic card #1 consists of a preconfigured in a 384-well format to assess 
the expression of 355 GPCR genes. The card #2 has 365 GPCR genes as well as 4 olfactives 
GPCR. The cards were then centrifuged twice in custom Buckets (Applied Biosystems, CA 
USA) in a Heraeus centrifuge (Kendro Scientific, Asheville, NC, USA) for 1 min at 1200 rpm. 
The cards were immediately sealed with the TaqMan Low-Density Array Sealer (Applied 
Biosystems, CA USA) to prevent any cross-contamination. Real-time RT-PCR is then 
performed on an ABI Prism 7900 (Applied Biosystems, Foster City, CA). Thermal cycling, to 
activate uracil-DNA glycosylase, is carried out for 2 min at 50°C, 10 min at 94.5°C then 40 
cycles of 30 s at 97 °C and 60 s at 59.7 °C. Each reaction contained cDNA derived from 
around 1.5 ng of total RNA. 
2.6 Statistics 
Real-time RT-PCR data were quantified using the SDS 2.2.1 software package (Applied 
Biosystems). Results were quantified in a relative comparative study, using an automatic 
baseline and threshold to record the cycle thresholds (Cts) setting and the 18S rRNA gene 
expression as a reference for normalization (ΔCts). Student's t-test was used with a 
significance threshold of P < 0.05. ELISA data are expressed as a percentage of the basal 
cytokine secretion level or as means (± SE); ‘n’ refers to the number of experiments. Results 
were compared using the non-parametric Mann–Whitney U test. The level of statistical 
significance was fixed at P < 0.05. 
3. Results  
By monitoring non-orphan RCPGs (i.e. 279 among the 382 RCPGs tested) in PBMCs of 10 
healthy donors and 10 CD patients we found that the data obtained were highly dependent 
on RNA integrity. The integrity of RNA molecules is of paramount importance for 
experiments that try to reflect the snapshot of gene expression at the moment of RNA 
extraction. The RNA integrity number (RIN) is an important tool regrettably often 
disregarded, in conducting valid gene expression measurement experiments as real-time 
PCR or DNA microarray (Schroeder et al. 2006). After RIN determination of our 20 samples, 
only 4 CD patients and 4 paired healthy donors could be considered reliable due to sample 
degradation yet with handling and shipping in dry ice from the hospital to the laboratory. 
3.1 Standardization 
Figure 1 represented a Dot Blot reflecting dispersion of 10 Housekeeping genes (PBMCs and 
biopsies). Before standardization, values (Ct) of 10 genes presented a distribution around 
50% of the median of the samples. However gene GUSB had weaker variance and 
symmetrical distribution compared to median. The distribution of ARNr 18S values is 
relatively good compared to whole of other Housekeeping genes excepting two samples 
presenting extreme values. The literature relates that genes of the sugar metabolism were 
found deregulated in biopsies of IBD patients  (Dieckgraefe et al. 2000) this fact encouraged 
us to choose 18S RNA to standardize our samples. After standardization, genes generally 
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(A) 
 
(B) 
Fig. 1. Dot blot of 10 Housekeeping genes before (A) and after (B) standardization to 18S 
RNA. 
showed a weaker dispersion, but we noticed that several genes like PGK1, RPLP0 and B2M 
presented extreme values. The fact that 3 genes out of 10 Housekeeping genes are not 
standardized the same manner, states clearly that genes are connected to different ways of 
metabolism which ways are affected by cell deregulation. For example, many reports on 
ratios show that the level of GAPDH messenger does not remain constant. Even if the 
GAPDH gene was considered for years as a reference in genetic organization, expression 
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and regulation studies, recent evidences demonstrate that mammalian GAPDH displays a 
number of diverse activities unrelated to its glycolytic function. For example, GAPDH 
messenger variations of enzymatic activity are implied in many mechanisms as varied as 
replication of DNA, transport of nuclear ARN and organization of cytoskeletal (Sirover 
1999) as well as neurodegenerative diseases.(Tatton et al. 2000) 
3.2 Gene clustering 
Before seeking genes differentially expressed in statistical systems with two classes, we 
wanted to know if it is possible to group samples in classes that characterize them with 
profile genes and type of pathology of patient to differentiate CD and UC. We followed a 
supervised approach which data groups without existing classes. Procedure of clustering 
consists in classifying a whole of data in several subsets according to their similarities. Data 
of expression form a matrix whose lines correspond to genes, here genes common to both 
cards, and columns with 17 samples. First, data were filtered so general average of form of 
genes is lower than 38 Ct, then standardized compared to ARNr 18S. 
The tree diagram or dendrogram illustrates the arrangement of clusters produced by 
hierarchical clustering. The individuals who resemble the most to each other are gathered in 
the bottom of the tree. The length of the branches is proportional to their distance among 
each other. The matrix of expression data is coloured coded according to the relative level of 
gene expression of genes: colours go from green for level of high expression to red for level 
of low expression, with black for intermediate level (units expressed in Ct). 
Figure 2 shows an ascending hierarchical classification by using Pearson's coefficient of 
correlation to measure the distance between two points. This distance reflects proximity or 
similarity between two points. Using Euclidean distance, which measures dissimilarity 
between two points and is more sensitive to amplitude of variations between data, produces 
regrouping of the data as illustrated into Figure 3. 
The data regrouping are obtained in form of two dendrograms, for genes and for 
individuals for each card. Classification distributes samples in 2 principals groups, PBMCs 
and biopsies. This first scission marks differences related nature of tissues. Then within each 
one of these 2 regroupings, we distinguish sub-groups: 
- for the PBMC group: the subgroup of healthy individuals differs markedly from that of 
patients with CD, each of these subgroups appear marginally affected by treatment 
with LPS. 
- for the biopsy group: the formation of sub-groups is less obvious, as is the 
interpenetration of these sub-groups: healthy subjects, healthy areas of patients with 
CD, healthy areas of patients with UC and inflammatory areas in patients with CD , 
inflammatory areas in patients with UC, and finally mucosa of patients with IBS. This 
behavior is certainly due to an insufficient number of samples representing each class, 
including healthy people and healthy areas of patients. These ambiguous groupings of 
biopsies outside their own classes indicate a high level of variation in gene expression 
in samples. 
In addition, dispersion curves (fig. 4 and 5) illustrate the heterogeneity of genes form in 
samples supposed to represent the same IBS. The correlation curves expression data of 
biopsies from inflammatory areas of patients with UC show a large dispersion of values in 
contrast to results obtained with patients CD. Indeed, the correlation coefficient of patients 
with UC or IBS is much lower (near 0.6) than that obtained with the data on three areas of 
biopsies from patients with inflammatory CD (around 0.8) 
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Fig. 2. GPCRs expression profile by ascending hierarchical classification of the samples. 
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Fig. 3. Ascending hierarchical classification using Euclidean distance to measure 
dissimilarity and average enters groups for algorithm of aggregation. 
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            (A)              (B) 
Fig. 4. Gene dispersion curves for CD (A) and IBS (B) biopsies. 
 
 
            (A)              (B) 
Fig. 5. Gene dispersion curves for CD (A) and UC (B) biopsies. 
The origins of these dispersions are many. First, in a technical point of view, the collection is 
a delicate operation to achieve in the bowel (colonoscopy) and the removal of the tissue 
requires expertise to pick the exact target area by damaging the minimum completeness of 
tissue removed. On the other hand, in a biological point of view, the heterogeneity of 
individuals (age, sex, treatment, diet, etc..) And the exact position where the taking is in the 
intestinal tract, are major sources of heterogeneity. The difficulty of our work was to remove 
background noise genes specifically associated with CD. In addition, changes in profiles of 
biopsies may represent different levels of evolution and development of the disease. Indeed, 
there may be a great variability of samples supposed to represent a single disease state or 
biological replicas considered in the statistical analysis. To achieve this level of 
interpretation, the data should be obtained on a large number of individuals in a population 
well characterized.  
This grouping study provides assurance that the GPCR expression profiles in PBMCs can 
distinguish CD from healthy subjects. It shows, however, the existence of heterogeneity of 
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expression profiles of GPCR and a large variance in the expression of genes in the biopsies, 
this should not be overlooked when analysing the data. 
3.3 Normal distribution of data 
Parametric statistical tests on the means involve the estimation of parameters such as 
variance. These tests are generally more powerful than nonparametric tests, but require as a 
condition for applying the normality of data distribution of the mean. Although the tests 
called parametric tests are quite robust, i.e. are insensitive to a deviation from normality (as 
long as you estimate the variance) and are often used as the mode of data distribution 
deviates slightly of normality, it is useful to test the normality of data distribution. 
We used the correlation test of Ryan-Joiner, similar to the Shapiro-Wilk test, as proposed in 
the Minitab software. The test generates a line of Henry and performs a hypothesis test to 
see if the observations are normally distributed. The assumptions of the test are: H0, the 
data follow a normal distribution against H1, the data do not follow a normal distribution. 
Using this test, we submitted the data from 9 housekeeping genes (Table 2) thru the 27 
samples for the goodness of fit to a Gaussian distribution. 
 
Gene 
symbol 
Assai ID Gene Name NCBI gene 
reference 
Chromo-
some 
RPLP0 Hs99999902_m1 Ribosomal protein, large, P0 NM_053275 12 
PPIA Hs99999904_m1 Peptidylprolyl isomerase A (cyclophilin A) NM_203430 7 
GAPD Hs99999905_m1 Glyceraldehyde-3-phosphate dehydrogenase NM_002046 12 
HIST1H1C Hs00271185_s1 Histone 1, H1c NM_005319 6 
HPRT1 Hs99999909_m1 Hypoxanthine phosphoribosyltransferase 1 NM_000194 X 
HSPCA Hs00743767_sH Heat shock 90kDa protein, 1 alpha NM_005348 14 
PGK1 Hs99999906_m1 Phosphoglycerate kinase 1 NM_000291 X 
K-ALPHA-1 Hs00744842_sH Tubulin, alpha, ubiquitous NM_006082 12 
RARS Hs00259879_m1 Arginyl-tRNA synthetase NM_002887 5 
ACTB Hs99999903_m1 Actin, beta NM_001101 7 
B2M Hs99999907_m1 Beta-2-microglobulin NM_004048 15 
CYC1 Hs00357717_m1 Cytochrome c-1 NM_001916 8 
GUSB Hs99999908_m1 Glucuronidase, beta NM_000181 7 
TFRC Hs99999911_m1 Transferrin receptor (p90, CD71) NM_003234 3 
NUP62 Hs00383013_m1 Nucleoporin 62kDa NM_153719 19 
18S  Ribosomal RNA 18S   
Table 2. Housekeeping list presents in the Applied Biosytem microfluidic card. 
Of the nine genes tested, 7 of them verify the hypothesis H0, the data follow the normal 
distribution, the risk of first type  of 0.01 (Figure 6). Only two genes, PGK1 and B2M have p 
values less than 0.01. These results can be linked with the dispersal rate of expression of 
these genes, as was noted earlier. The test results are for a normal distribution of data and 
give us confidence in using the Student test. 
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Fig. 6. Test of normality by the Ryan-Joiner test of correlation. The vertical axis represents 
scale of probabilities and horizontal axis scale of data. A line of least squares is adjusted at 
raised points and is traced on graph for reference. The line represents an estimate of 
function of pattern of settlement from where data are extracted. The estimates of parameters 
average and standard deviations of population are posted under graph. 
3.4 Gene expression in PBMCs of CD patients versus control 
It is now widely accepted that GPCRs, including cytokine receptors play a critical role in 
controlling the inflammatory response (Luther & Cyster 2001; Onuffer & Horuk 2002; 
Thelen 2001). It has been shown that immune cells express many receptors of neuropeptides 
and neurotransmitters, highlighting the role of mediators in the neuroendocrine modulation 
of immune response. In addition, there is a bundle of evidence indicating the existence of 
relationship between GPCR signaling pathways and answers related to antigen receptor of T 
cells and interleukin-2. Thus, prostaglandins produced by activated macrophages during 
the immune response can inhibit both cytokine production and proliferation of T cells 
(Baker et al. 1981). These observations motivated us to work with PBMCs, a more 
homogeneous cell population much less restrictive than the colon biopsies of patients. In our 
study on PBMCs taken from four healthy subjects and four patients with CD in remission, 
the expression profiles of GPCRs were obtained on card #1. 
The genes were previously filtered to eliminate those not expressed in any of the samples, so 
that they are about 85 genes remaining. The were two reason of this operation: i) reduce 
variance brought by genes not expressed during calculation of ∆Ct since these genes have Ct 
equal to 40; ii) avoid null denominators in calculations in particular standard deviations. This 
does not mean that all 296 selected genes are expressed. Values are normalized to 18S rRNA in 
each sample. The differentially expressed genes between the normal subjects and CD patients 
were obtained from the p-value of the Student test at risk of type  equal to 0.05. The 
difference in expression between the two classes of individuals was determined from the 
difference between the average ΔCt healthy subjects and the average ΔCt of CD patients. 
∆∆Ct = (∆Cthealthy- ∆CtCD) 
The data of the 22 differentially expressed genes were subjected to a nonparametric test, 
more robust and less sensitive to extreme values. The Mann-Whitney test for unpaired data 
with Minitab software calculates the value p and focuses on the equality of medians of two 
groups. Figure 7 shows two examples of the report of the results for Minitab for gene SSTR5 
and ADRA2B for a threshold of the first kind  of 0.05. The data of the first gene name can 
reject the hypothesis H0 while those of ADRA2B does not allow it. 
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Assay ID 
Gene 
Symbol 
Gene Name T-TEST ∆∆Ct Standard 
Deviation 
Mann-Whitney 
test 
Hs00664150_s1 MRGPRE
MAS-related GPR, 
member E 
0.007 9.8 2.10 Rejection 
Hs00265647_s1 SSTR5 somatostatin receptor 5 0.038 9.6 2.50 Rejection 
Hs00664166_s1 GPR142 
G protein-coupled 
receptor 142 
0.011 9.5 2.22 Rejection 
Hs00270999_s1 GPR4 
G protein-coupled 
receptor 4 
0.018 8.4 2.15 Rejection 
Hs00266671_s1 FY Duffy blood group 0.020 7.8 2.26 Rejection 
Hs00265617_s1 SSTR1 somatostatin receptor 1 0.024 7.8 2.10 Rejection 
Hs00664089_s1 GPR148 
G protein-coupled 
receptor 148 
0.023 7.6 2.19 Rejection 
Hs00275980_s1 PPYR1 
pancreatic polypeptide 
receptor 1 
0.022 7.3 2.39 Rejection 
Hs00271049_s1 GPR20 
G protein-coupled 
receptor 20 
0.017 7.2 2.35 Rejection 
Hs00265195_s1 CHRM1 
cholinergic receptor, 
muscarinic 1 
0.035 6.7 2.15 Rejection 
Hs00271017_s1 GPR7 
G protein-coupled 
receptor 7 
0.030 6.3 2.16 Rejection 
Hs00271023_s1 GPR8 
G protein-coupled 
receptor 8 
0.002 6.1 1.52 No rejection 
Hs00664201_s1 BDKRB1 bradykinin receptor B1 0.049 5.8 2.19 No rejection 
Hs00271008_s1 GPR6 
G protein-coupled 
receptor 6 
0.044 5.5 2.03 No rejection 
Hs00706455_s1 CCR10 
chemokine (C-C motif) 
receptor 10 
0.015 5.3 2.02 No rejection 
Hs00268954_s1 FZD9 
frizzled homolog 9 
(Drosophila) 
0.016 5.3 1.86 No rejection 
Hs00265090_s1 ADRA2B 
adrenergic, alpha-2B-, 
receptor 
0.047 4.5 1.96 No rejection 
Hs00265286_s1 HTR1B 
5-hydroxytryptamine 
(serotonin) receptor 1B 
0.026 4.1 1.57 No rejection 
Hs00184657_m1 BAI2 
brain-specific 
angiogenesis inhibitor 2
0.041 -2.4 1.44 No rejection 
Hs00222094_m1 HRH4 histamine receptor H4 0.050 -2.5 1.57 No rejection 
Hs00181231_m1 ADORA1 adenosine A1 receptor 0.028 -3.3 1.74 No rejection 
Hs00173471_m1 OPRL1 opiate receptor-like 1 0.004 -5.1 1.71 Rejection 
Table 3. Results of p-values for 22 genes. 
The results of the p-values have been reported in Table 3: 14 of 22 genes confirmed the 
results of the parametric test (MRGPRE, SSTR5, GPR142, GPR4, FY, SSTR1, GPR148, PPYR1, 
GPR20, CHRM1, GPR7, FZD9, and HTR1B OPRL1). 
The Mann-Whitney, which addresses to data from samples drawn randomly and 
independently in two populations of the same variance, is limited here by the low number 
of individuals tested. Having duplicate data, that is to say to increase the "NR" to 8 instead 
of 4 and keeping the same values of the medians, produces a p-value less than 0.05. All 
genes in Table 3 for which the hypothesis H0 could be rejected for NR equal to 4, are 
regarded significantly different by the mere fact of double samples. This is proven by a ratio 
of Minitab for ADRA2B with NR equal to 8. 
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Knowing that the signed rank test 2-sample is slightly less powerful than the test samples 
with 2 grouping of sample variance when the populations are normal, and taking into 
account the recommendations of Minitab software for populations with different standard 
deviations, we have privileged a 2-sample t test without pooling the variances for the 
analysis of differential genes. 
Of the 22 genes differentially expressed in PBMC of CD patients compared to normal subjects, 
18 were overexpressed, while four are under-expressed. The overexpressed genes are mostly 
induced in the disease except ADRA2B and GPR8 receptors that are expressed in PBMCs of 
normal subjects. Among these genes are receptors involved in the inflammatory and immune 
(SSTR5, SSTR1, CHRM1, CCR10, FY, BDKRB1, HTR1B) in other processes (MRGPRE, PPYR1, 
FZD9) and unknown functions (7 orphan receptors: GPR4, GPR142, GPR148, GPR20, GPR7, 
GPR8, GPR6). In a similar approach, Burczynski ME and collaborators research in PBMC gene 
expression signatures to discriminate CD of UC. They used the Affymetrix microarray 
platform HG-U133A that allows you to query more than 22 000 genes with a sample of 42 
normal individuals and 59 CD patients (Burczynski et al. 2006). Their data were deposited in 
the database of microarrays GEO "Gene Expression Omnibus" at NCBI and are available to the 
community in the form of CEL files. CEL files are files that contain Affymetrix raw data. The 
site also allows to directly visualize the expression profile of a gene selected from across all 
samples as a histogram. Out of the 22 genes on the TLDA microfluidic cards, 16 are present on 
the chip. By submitting data at the same t-test that was used at the threshold 0.05, 5 genes 
appear differentially expressed in CD patients compared to normal individuals (FZD9, SSTR1, 
CCR10, HTR1B, OPRL1) with reports of expression ranging from 1.83 (FZD9) and 0.75 
(OPRL1). The very low expression of these 16 genes on the chip confirms the absence of 
expression observed in real-time PCR in healthy individuals (SSTR5, SSTR1, FZD9, CCR10, 
HTR1B, GPR6, FY, ADORA1, BDKRB1, PPYR1, GPR20, GPR4). The discrepancy concerning the 
magnitude of changes in expression levels (less than 2 with the microarray against values 
higher then 16 in real-time PCR) between the two sets of data can be related to the difference in 
sensitivity of two technologies, real-time PCR being much more sensitive than the 
oligonucleotide hybridization technique. 
 
 
           (A)              (B) 
Fig. 7. Validation of results obtained by real-time PCR in 96 well plates as compared to 
LDTA card. (A) Correlation curve for SSTR5 data. (B) Ratio of expression rates between CD 
patient and disease free individuals for 3 somatostatin receptors for data obtained by using 
microfluidic cards or 96 plates technology.. 
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The presence among this group of receptor genes in the same family, SSTR1 and SSTR5, 
which in addition show a strong increase of expression in CD patients, is interesting. This 
prompted us to conduct a new measurement of the expression of these genes by real-time 
PCR but using 96-well plate format. This makes it possible to assess the performance of the 
microfluidic card system, i.e. if the differences of expression come from technology, 
rheology, the depot of the tests in the cards, etc. Complementary DNA has been a 
resynthesized from total RNA and PCR was conducted under the same conditions of 
reagents on the ABI Prism 7000 thermocycler. We add to the experience another 
somatostatin receptor, SSTR3, whose expression is unchanged in microfluidic card TLDA. 
The histogram in Figure 7 confirms the results achieved with the microfluidic card and the 
curve (Fig.7A) shows good correlation between measurements of two technologies. 
3.5 Healthy subjects and CD patients with LPS activation 
We tested the ability of PBMC from healthy individuals and CD patients with to induce the 
production of TNF- in response to LPS stimulation. After 24 hours incubation with LPS, we 
measured the release of TNF-. We observed a production of TNF-α in the two groups of 
people consolidating us on the effectiveness of PBMC to respond to LPS. PBMCs of CD 
patients produce TNF- twice as much as healthy subjects (data not shown).  
Concerning gene expression, the data analysis was performed using an approach similar to 
the one described before. However, we applied here more strict filters by removing genes 
whose mean Ct was greater than 37. In this area of values measuring variations are 
significant. They are due on the one hand to the lack of reproducibility of withdrawals that 
is related to the Gaussian distribution of the sample in a solution containing a small number 
of copies of cDNA, and secondly, the SDS software that assigns a Ct of 40 to genes for which 
the amplification curve does not reach a plateau, as they cross the threshold between the 
37th and 40th cycle. 
Values were first normalized to 18S rRNA then for each individual, the difference of ∆Cts, 
the ∆∆Cts between the PBMC stimulated or not by LPS was computed. We also calculated 
the average values of ∆∆Cts obtained from four individuals. The genes whose expression is 
regulated by the activation of PBMC by LPS in normal subjects were selected on the one 
hand for an average of ∆∆Cts values greater than 1.5 and less than -1.5, and to the other 
from the p-value of Student's test for paired data at risk of Type  equal to 0.05. We obtained 
18 genes (Table 4) whose expression is significantly LPS dependent, of which 4 are 
overexpressed and 14 repressed. With the exception of GPRC5A the three overexpressed 
genes (GPR155, SSTR3, H963) are well expressed in the non-activated PBMC from healthy 
subjects. Among these genes are many receptors known to be involved in the inflammatory 
process and immune response (EDG2, EMR2, EMR3, CCR1, GPR35, FPr1, CCR3, CMKLR1, 
C5R1, FPRL2, P2RY2, GPBAR1) with two orphan receptors (GPR77, GPR162). 
The same experiment conducted with PBMC from CD patients, stimulated or not with LPS, 
shows a profile of genes regulated by LPS very similar to that obtained in healthy subjects, 
but with a more important difference between those genes induced and repressed (1 for 19 
genes) (Table 5). The appearance of genes such as CCR5, EDG3, EDNRB and IL8RB 
strengthens families of genes already controlled by LPS in healthy subjects. We also observe 
an effect of LPS on the expression of neuropeptide receptors, BAI1, and HTR1A NTSR1. 
Conversely, LPS does not seem to affect the expression of GPRC5A, SSTR3, H963, EMR2 and 
EMR1 genes in CD patients. 
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Assay ID 
Gene 
symbol 
Gene Name 
T-
TEST 
Average 
ΔCt 
Hs00173681_m1 GPRC5A retinoic acid induced 3 0.023 4.9 
Hs00400624_m1 GPR155 G protein-coupled receptor 155 0.026 2.2 
Hs00265633_s1 SSTR3 somatostatin receptor 3 0.005 1.6 
Hs00664328_s1 H963 platelet activating receptor homolog 0.027 1.5 
Hs00173500_m1 EDG2 
endothelial differentiation, lysophosphatidic 
acid GPCR 2 
0.036 -1.7 
Hs00203752_m1 EMR2 
egf-like module containing, mucin-like, 
hormone receptor-like 2 
0.006 -1.8 
Hs00261470_m1 EMR3 
egf-like module containing, mucin-like, 
hormone receptor-like 3 
0.028 -2.1 
Hs00174298_m1 CCR1 chemokine (C-C motif) receptor 1 0.016 -2.2 
Hs00271114_s1 GPR35 G protein-coupled receptor 35 0.005 -2.4 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.002 -2.9 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.031 -2.9 
Hs00356604_m1 CMKLR1 chemokine-like receptor 1 0.034 -3.0 
Hs00356609_g1 C5AR1 
complement component 5 receptor 1 (C5a 
ligand) 
0.006 -3.7 
Hs00266666_s1 FPRL2 formyl peptide receptor-like 2 0.011 -3.9 
Hs00175732_m1 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 0.011 -4.4 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.038 -4.5 
Hs00248078_m1 GPR162
likely ortholog of mouse gene rich cluster, A 
gene 
0.004 -5.0 
Hs00544894_m1 GPBAR1 G protein-coupled bile acid receptor 1 0.008 -5.4 
Table 4. Genes differentially expressed between PBMCs of control subjects stimulated or not 
by LPS. Test ID: test Taqman Applied Biosystems identification; T-TEST: value p of the test 
of Student for paired data; Average of ΔΔCts: average of the difference of ΔΔCt (ΔCthealthy - 
ΔC Cthealthy +LPS) for each individual. The average of ΔΔCts is positive for overexpressed 
genes and negative for under-expressed genes. 
To search for genes regulated by LPS in a different manner in healthy individuals and 
patients with CD, we used a t test for unpaired data. Table 6 shows the three genes: P2RY2 
gene is repressed by LPS in healthy subjects while remaining unaffected in CD patients, 
CCR5 gene is repressed only in CD patients, the gene GPR4 appears for a regulation in the 
opposite direction depending on whether LPS acts on PBMC from healthy individuals or 
CD patients. The difference of expression of GPR4 between patients and healthy becomes 
significant. It is interesting to note that the GPR4 gene was increased in PBMC of CD 
patients without LPS treatment. To these genes we might add the genes that appear only 
with the healthy or disease group like SSTR3, H963, GPRC5A, EMR2 and EMR3for the 
healthy or NTSR1, EDG3 and GPRAR for CD patients, but there is not enough statistical 
evidence at this level of the study to consider these genes differentially expressed between 
healthy subjects and patients. 
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Assay ID 
Gene 
Symbol
Gene Name T-TEST 
Average 
Cts 
Hs00400624_m1 GPR155 G protein-coupled receptor 155 0.031 1.8 
Hs00181777_m1 BAI1 brain-specific angiogenesis inhibitor 1 0.025 -1.7 
Hs00173500_m1 EDG2 
endothelial differentiation, 
lysophosphatidic acid GPCR 2 
0.039 -1.8 
Hs00265014_s1 HTR1A
5-hydroxytryptamine (serotonin) 
receptor 1A 
0.018 -1.8 
Hs00152917_m1 CCR5 chemokine (C-C motif) receptor 5 0.003 -1.9 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.004 -2.2 
Hs00265090_s1 ADRA2B adrenergic, alpha-2B-, receptor 0.041 -2.2 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.007 -2.3 
Hs00356604_m1 CMKLR1 chemokine-like receptor 1 0.021 -2.3 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.034 -2.6 
Hs00174298_m1 CCR1 chemokine (C-C motif) receptor 1 0.007 -3.4 
Hs00173592_m1 NTSR1 neurotensin receptor 1 (high affinity) 0.008 -3.6 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.033 -3.7 
Hs00266666_s1 FPRL2 formyl peptide receptor-like 2 0.000 -3.8 
Hs00356609_g1 C5AR1 
complement component 5 receptor 1 
(C5a ligand) 
0.004 -4.0 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.003 -4.0 
Hs00245464_s1 EDG3 
endothelial differentiation, sphingolipid 
GPCR 3 
0.003 -4.1 
Hs00240747_m1 EDNRB endothelin receptor type B 0.010 -4.3 
Hs00544894_m1 GPBAR1 G protein-coupled bile acid receptor 1 0.026 -5.2 
Hs00248078_m1 GPR162
likely ortholog of mouse gene rich cluster, 
A gene 
0.014 -6.9 
Table 5. Genes differentially expressed between PBMC of CD patients stimulated or not by 
LPS. Test ID: Taqman Applied Biosystems identification test; T-TEST: value p of the test of 
Student for paired data; Average of Cts: average of the difference of Ct (CtCD - C 
CtCD+LPS) for each individual. The average of Cts is positive for overexpressed genes and 
negative if under-expressed. 
 
Assai ID 
Gene 
Symbol 
Gene Name 
T-
TEST
Average 
Cts 
Hs00175732_m1 P2RY2 
purinergic receptor P2Y, G-protein 
coupled, 2 
0.049 3.4 
Hs00152917_m1 CCR5 chemokine (C-C motif) receptor 5 0.003 -1.5 
Hs00270999_s1 GPR4 G protein-coupled receptor 4 0.028 -5.7 
Table 6. Genes differentially expressed in PBMCs stimulated by LPS between control and 
CD patients. 
3.6 Expression profiles in biopsies 
Biopsies from healthy subjects, CD, UC and IBS patients were analyzed. Data were obtained 
with the microfluidic card#2 dedicated to GPCR transcriptome. The results presented were 
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obtained from 11 biopsies taken from a sampling of heterogeneous individuals: one biopsy 
of healthy individuals, four zones of patients with inflammatory CD and a healthy area of a 
patient with CD, inflammatory zone 2 of patients with UC and a healthy area of a patient 
with UC, and 2 from patients with IBS. The results presented were obtained from 11 
biopsies taken heterogeneous individuals: 1 biopsy of healthy individual only, 4 inflamed 
zones of CD patients and one healthy zone of CD patients, 2 inflamed zones of UC patients 
and a healthy zone of UC patient, and 2 inflamed zones of IBS patients. 
Due to the heterogeneity and the small number of individuals studied, we tried to present 
here the most interesting results in spite of all possible combinations. It seemed wise to seek 
for receptors that expressed specifically in inflamed CD tissue relative to all other samples, 
biopsy of the healthy individual and those of patients with UC or IBS. This procedure is like 
comparing the inflammatory tissue of CD with background noise resulting from the 
combination of all other tissues. To do this, we used the same approach of comparing 
expression profiles of PBMCs from healthy subjects and patients with a Student test for 
unpaired data (α equal to 0.05) and the calculation of ∆∆Ct averages of two classes (∆∆Ct = 
(∆Ct non-CD- ∆Ct CD)). The genes were filtered with the criteria of an average of Cts lower than 
37 and selected for ∆∆Ct higher than 1.5. Thus Table 8 shows 37 genes differentially 
expressed between biopsies from inflamed zone of CD patients and all the other biopsies 
(healthy individual, healthy area of CD patient, areas of healthy and inflammatory UC 
patients and IBS). All 37 genes are overexpressed in CD. 
Given the large number of genes revealed, we relied on the David software to highlight the 
functional categories appropriately represented in an expression profile. David is a Web 
application of NCBI that uses the NCBI GO terms (Gene Ontology) a vocabulary structured 
to describe role of genes and their products (The Gene Ontology Consortium, 2001). David 
interprets terms GO associated with differentially found genes and alternatively compares 
them with whole of functional categories of genes present on card#2, alternately against the 
studied genome. Under "immune response", appeared a group of seven genes, including 
many chemokine receptors (ADORA1, BLR1, CNR2, CCR6, CCR7, CCR8, IL8RA, IL8RB). This 
group corresponds to an ontology enrichment of a factor 2 (8/33 compared to 49/362 in 
map 2). One can note the strong representation of genes related to neuropeptides, receptor 
proteins are 17 out of 33 (33 of the 37 gene list have a GO term). However, these receptors do 
not represent enrichment since they are 162 listed in this category. 
We looked for genes characteristic of different types of inflammation of the intestine: IBS, 
UC and CD. To do this we compare the three groups of tissue two by two and used the 
criteria previously used to identify "differential" genes. Tables 8 to 11 represent the genes 
obtained. Table 11 shows a greater number of "differential" genes between inflamed zones 
between IBS patients and CD patients. All 19 genes are increasing in CD up to several orders 
of magnitude. These genes are composed in a large majority of neuropeptides receptors. 
There are also many orphan receptors, like the TAAR family ("Trace Amine Associated 
Receptor"), for which ligands are likely to have similarities with the metabolites of amino 
acids as neurotransmitters. 
Table 12 shows 4 "differential" genes between UC and IBS: 3 orphan receptors are increased 
in UC biopsies whereas receptor of chemokine CCBP2 is reduced. Between biopsies of UC 
and CD (table 10), there are very few genes that are significantly "differently" expressed. 
Note that among four neuropeptide receptors, two are receptors for peptides from the brain 
(vasopressin and parathyroid hormone). These hormone receptors may reflect a special 
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relationship of inflammatory bowel area with the central nervous system.  Those genes are 
the significantly different between UC and CD. 
 
Assay ID Gene Symbol Gene Name T-TEST 
Average 
Cts 
Hs00609865_m1 EDNRA endothelin receptor type A 0.002 6.6 
Hs00174146_m1 IL8RA interleukin 8 receptor, alpha 0.035 6.0 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.008 5.3 
Hs00167241_m1 HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 0.007 4.4 
Hs00223340_m1 GPR147 G protein-coupled receptor 147 0.006 4.2 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.044 3.8 
Hs00173855_m1 GPR putative G protein coupled receptor 0.002 3.6 
Hs00176122_m1 AVPR1A arginine vasopressin receptor 1A 0.002 3.4 
Hs00200681_m1 ADMR adrenomedullin receptor 0.049 3.3 
Hs00542381_m1 GPR114 G protein-coupled receptor 114 0.015 3.2 
Hs00174895_m1 PTHR1 parathyroid hormone receptor 1 0.007 3.1 
Hs00171054_m1 CCR7 chemokine (C-C motif) receptor 7 0.001 3.0 
Hs00332805_m1 MRGPRF MAS-related GPR, member F 0.003 3.0 
Hs00736776_m1 P2RY8 purinergic receptor P2Y, G-protein coupled, 8 0.002 3.0 
Hs00212116_m1 GPRC5B GPCR, family C, group 5, member B 0.009 3.0 
Hs00168765_m1 PTGIR prostaglandin I2 (prostacyclin) receptor (IP) 0.027 2.9 
Hs00174764_m1 CCR8 chemokine (C-C motif) receptor 8 0.016 2.9 
Hs00361490_m1 CNR2 cannabinoid receptor 2 (macrophage) 0.028 2.7 
Hs00266671_s1 FY Duffy blood group 0.040 2.7 
Hs00391810_m1 GPR116 G protein-coupled receptor 116 0.009 2.6 
Hs00237052_m1 CXCR4 chemokine (C-X-C motif) receptor 4 0.006 2.4 
Hs00272624_s1 CYSLTR1 cysteinyl leukotriene receptor 1 0.040 2.4 
Hs00174910_m1 TSHR thyroid stimulating hormone receptor 0.030 2.4 
Hs00168763_m1 PTGFR prostaglandin F receptor (FP) 0.028 2.3 
Hs00187982_m1 F2RL2 coagulation factor II (thrombin) receptor-like 2 0.047 2.3 
Hs00173499_m1 EDG1 
endothelial differentiation, sphingolipid  
GPCR 1 
0.010 2.2 
Hs00173527_m1 BLR1 
Burkitt lymphoma receptor 1, GTP binding 
protein (chemokine (C-X-C motif) receptor 5)
0.022 2.2 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.035 2.2 
Hs00170665_m1 SMO smoothened homolog (Drosophila) 0.043 2.1 
Hs00262150_m1 GPR124 G protein-coupled receptor 124 0.026 2.1 
Hs00274326_s1 P2RY10 purinergic receptor P2Y, G-protein coupled, 10 0.034 2.0 
Hs00181231_m1 ADORA1 adenosine A1 receptor 0.042 2.0 
Hs00246222_s1 NPY6R neuropeptide Y receptor Y6 (pseudogene) 0.026 2.0 
Hs00168362_m1 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 0.038 1.9 
Hs00173787_m1 CALCRL calcitonin receptor-like 0.028 1.9 
Hs00169258_m1 F2R coagulation factor II (thrombin) receptor 0.030 1.8 
Hs00270873_s1 AGTRL1 angiotensin II receptor-like 1 0.026 1.8 
Hs00171121_m1 CCR6 chemokine (C-C motif) receptor 6 0.009 1.8 
 
Table 7. Genes differentially expressed between biopsies of inflamed zone CD patients and 
biopsies of colon (healthy individual, healthy zone of the CD patient, healthy and inflamed 
zones of UC patients, inflamed zones of IBS patients). 
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Assay ID 
Gene 
Symbol 
Gene Name 
T-
TEST 
Average 
Cts 
Hs00174146_m1 IL8RA interleukin 8 receptor, alpha 0.002 10.8 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.035 8.4 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.023 7.9 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.025 6.1 
Hs00223340_m1 GPR147 G protein-coupled receptor 147 0.010 5.9 
Hs00271072_s1 GPR23 G protein-coupled receptor 23 0.043 5.8 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.035 5.1 
Hs00256749_s1 P2RY13 purinergic receptor P2Y, G-protein coupled, 13 0.012 4.0 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.034 3.7 
Hs00261470_m1 EMR3 
egf-like module containing, mucin-like, hormone 
receptor-like 3 
0.040 3.6 
Hs00269446_s1 EDG6 
endothelial differentiation, G-protein-coupled  
receptor 6 
0.046 3.6 
Hs00252658_s1 CYSLTR2 cysteinyl leukotriene receptor 2 0.015 3.1 
Hs00171054_m1 CCR7 chemokine (C-C motif) receptor 7 0.012 2.9 
Hs00542381_m1 GPR114 G protein-coupled receptor 114 0.031 2.8 
Hs00274326_s1 P2RY10 purinergic receptor P2Y, G-protein coupled, 10 0.027 2.4 
Hs00252888_s1 VN1R1 vomeronasal 1 receptor 1 0.040 1.7 
Hs00176738_m1 MATK megakaryocyte-associated tyrosine kinase 0.041 -1.3 
Hs00191104_m1 GPR37L1 G-protein coupled receptor 37 like 1 0.039 -4.8 
Table 8. Genes differentially expressed between biopsies of inflamed zone of CD patients, 
and biopsies of healthy individual and patients having IBS. 
 
Assay ID Gene Symbol Gene Name T-TEST Average Cts 
Hs00266671_s1 FY Duffy blood group 0.040 2.7 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.035 2.2 
Hs00181231_m1 ADORA1 adenosine A1 receptor 0.042 2.0 
Table 9. Common genes differentially expressed between biopsies of inflamed zone and 
PBMCs of CD patients. 
 
Assay ID Gene Symbol Gene Name 
T-
TEST
Average Cts 
Hs00174895_m1 PTHR1 parathyroid hormone receptor 1 0.001 3.9 
Hs00176122_m1 AVPR1A Arginine vasopressin receptor 1A 0.007 2.7 
Hs00184657_m1 BAI2 brain-specific angiogenesis inhibitor 2 0.029 2.2 
Hs00265081_s1 ADRA2A adrenergic, alpha-2A-, receptor 0.044 2.1 
Hs00174304_m1 IL8RB interleukin 8 receptor, beta 0.004 -2.2 
Hs00266213_s1 CCR3 chemokine (C-C motif) receptor 3 0.007 -2.3 
Hs00181830_m1 FPR1 formyl peptide receptor 1 0.034 -2.6 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.033 -3.7 
Hs00218495_m1 GPR77 G protein-coupled receptor 77 0.003 -4.0 
Table 10. Genes differentially expressed between biopsies of inflamed zone of CD patients 
and biopsies of inflamed zone of UC patients. 
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Assay ID 
Gene 
Symbol 
Gene Name 
T-
TEST 
Average 
Cts 
Hs00601815_s1 TAAR9 trace amine associated receptor 9 0.010 11.7 
Hs00365019_s1 MRGPRX2 MAS-related GPR, member X2 0.009 11.4 
Hs00265296_s1 HTR1F 5-hydroxytryptamine (serotonin) receptor 1F 0.012 11.2 
Hs00609865_m1 EDNRA endothelin receptor type A 0.026 11.1 
Hs00174146_m1 IL8RA interleukin 8 receptor, alpha 0.006 11.1 
Hs00265208_s1 CHRM2 cholinergic receptor, muscarinic 2 0.000 9.9 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.012 9.4 
Hs00269590_s1 TAAR5 trace amine associated receptor 5 0.001 9.3 
Hs00754695_s1 MRGPRX3 MAS-related GPR, member X3 0.043 8.8 
Hs00265081_s1 ADRA2A adrenergic, alpha-2A-, receptor 0.036 8.6 
Hs00664049_s1 GPR150 G protein-coupled receptor 150 0.017 8.4 
Hs00274365_s1 TAAR2 trace amine associated receptor 2 0.002 7.4 
Hs00271072_s1 GPR23 G protein-coupled receptor 23 0.002 7.3 
Hs00664166_s1 GPR142 G protein-coupled receptor 142 0.044 6.9 
Hs00267157_s1 MAS1 MAS1 oncogene 0.003 6.2 
Hs00266671_s1 FY Duffy blood group 0.030 5.8 
Hs00271877_s1 CD4R Melanocortin 4 receptor 0.046 5.1 
Hs00269446_s1 EDG6 
endothelial differentiation, G-protein-coupled 
receptor 6 
0.029 4.5 
Hs00168567_m1 NPY2R Neuropeptide Y receptor Y2 0.032 3.3 
Table 11. Genes differentially expressed between biopsies of inflamed zone of CD patients 
and IBS patients. 
 
Assay ID 
Gene 
Symbol 
Gene Name T-TEST 
Average 
Cts 
Hs00220561_m1 GPR84 G protein-coupled receptor 84 0.044 8.0 
Hs00664166_s1 GPR142 G protein-coupled receptor 142 0.042 7.5 
Hs00542396_m1 GPR110 G protein-coupled receptor 110 0.008 4.9 
Hs00174299_m1 CCBP2 chemokine binding protein 2 0.039 -2.8 
Table 12. Genes differentially expressed between biopsies of inflamed zone of FGD patients 
and UC patients. 
4. Conclusion 
Studying the expression of GPCRs in PBMCs has highlighted a number of deregulated 
genes in CD. In general, among these deregulated genes, the majority is accepted to be 
involved in mechanisms of inflammation or immune response. After a closer examination of 
their function, these genes appear to have an opposite contribution in the inflammatory 
process. Surprisingly, receptor expression is regulated more in favor of a repressor or 
suppressor effect of a malfunction of inflammatory cells rather than in a pro-inflammatory 
activity like SSTR5 whose role is to reduce intestinal inflammation.  
Expression profiles of PBMC's GPCR distinguish CD patients from healthy donors are 
represented in Figure 10. The expression of a reduced number of genes makes it even clearly 
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feasible to differentiate PBMCs from healthy individuals and CD patients (Figure 11). These 
receptors could be a signature for CD, but it remains necessary to test this group of genes 
with other known genes, for healthy and CD PBMCs, and so to check if clustering classifies 
correctly these samples. It would be also interesting to compare these profiles with those 
obtained from PBMCs of patients developing IBS or UC. 
Our study activation of PBMCs by LPS shows that PBMCs are able to induce in vitro an 
immunizing response in answer to exposure to bacterial lipopolysaccharide of production 
and release in medium of TNF-, principal mediator of inflammatory answer. This 
activation of monocytes by LPS was amply described and used in routine way in 
laboratories to test capacity of monocytes to answer pathogenic microorganisms. Majority of 
human cells answer molecular signals of microbial invasion of installing locally mechanisms 
of defense, then by recruiting and activating specialized cells of immune system. 
 
 
Fig. 10. Signature of GPCR expression in PBMCs from CD patients (CD) versus healthy 
donors (H). Ascending hierarchic classification was carried out using the software Dchip (Li 
and Wong 2001) using a correlation matrix of distances and centroid grouping. The matrix 
of expression data is converted into a thermal colored map according to the relative level of 
expression of each gene.  The colors range from blue to a high level of expression to red for a 
low level of expression through an intermediate white (values expressed in ∆Ct). 
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Fig. 11. Signature of expression of GPCRs in biopsies of CD patients (MCxx), UC patients 
(RHCxx) and IBS patients (TFIxx). 
As has been described before, the recognition of TRL4 receptors on the surface of monocytes 
by a bacterial product such as LPS leads to a cascade of reactions within the cells and release 
of cytokines TNF-, but also IL-1, IL-3, I-6, IL-10, and colony stimulating factors (CSFs), 
chemokines such as IL-8 and macrophage inflammatory proteins (MIFs). The main 
mechanism underlying the induction of these proteins is at the level of transcription, 
particularly under the control of the transcription factor NF-B. We studied here the effect of 
bacterial stimuli in an original way, first by examining its effect on the expression of almost 
all GPCRs, second using a macro-arrays technology by real-time PCR. Our results indicate 
that activation of PBMC by LPS is reflected mainly by a repression of GPCR expression. In a 
similar approach conducted with larger arrays, the same trend was observed i.e. LPS 
represses 1125 genes out of 1868 differentially expressed genes (Wurfel et al. 2005). Among 
the overexpressed genes, these authors note the presence of key players in the inflammatory 
response, primarily cytokines and chemokines. In our hands the only GPCR in the list of 15 
genes selected in each category is the chemokine receptor 2 (CCR2) the 2nd most strongly 
repressed. If we noticed no decrease in CCR2, the experimental condition, origin of LPS, 
exposure time and concentration of LPS may explain this divergence of results. It is 
interesting to note that among genes repressed by LPS common to healthy individuals and 
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CD patients, two families of receptor are represented: chemokine receptors (CCR1, CCR3, 
CMKLR1, C5AR1) and formylated peptides receptors (FPR1, FPRL2). The receptors 
involved in chemotaxis and recognition of bacterial peptides (CCR1, CMKLR1, RPF) have 
been extensively documented for their repression following LPS activation of PBMCs 
(Boldrick et al. 2002; Nau et al. 2002; Parker et al. 2004). Others observed similar expression 
profiles in PBMCs (Boldrick et al. 2002). In addition, they noticed that the induction and 
repression are LPS dose dependent and there are some differences in the profiles along the 
microorganism and their virulence, suggesting that some pathogens have developed 
strategies to foil the defense mechanism of host cells. However we observe a suppression of 
two other chemokine receptors: CCR3, known to have high affinity for eotaxin, a chemokine 
produced by eosinophil in broncho-alveolar fluid in the animal model of asthma (Jose, 
Griffiths-Johnson et al. 1994) and C5AR1 studied in neutrophil chemotaxis and linked to 
many diseases immune complex. Other receptors whose function is less known (EDG2, 
GPBAR1) and especially 2 orphan receptors (GPR155 one of rare genes activated by LPS and 
GPR162 repressed by more than 100 times in CD patients) could provide new elements in 
understanding the signaling pathways that control the inflammatory response. 
The decrease in gene expression essential for the defense of an organism, while it is in 
contact with the invader, may seem paradoxical. One hypothesis is that these mechanisms of 
repression and induction of certain genes have a regulatory role for antigen-presenting cells 
(APC). This repression of genes, without which the massive amplification of defense 
systems quickly destroy infectious agents, allows the APC time to present antigens to T 
cells, not only at the site of infection but also in secondary lymphoid tissues. 
It should be noted that parallel to repression of certain receptors, most of their ligands, 
cytokines and chemokines, are increased by LPS (Boldrick et al. 2002). This hypothesis 
reinforces the concept of immune defense mechanism tightly controlled and orchestrated at 
the transcriptional level as highlighted by studying expression profiles over time. Thus, in 
monocytes, LPS controls temporally and alternately increase and decrease of expression of 
different groups of gene (Sharif et al. 2007). In the context of a specific program of control of 
gene expression, it is not surprising that the time, the origin and the dose of LPS are factors 
that influence the expression profile. It is interesting to note that in the work of Sharif and 
coll., 4 receptors of our repertory are among the 72 genes controlled by LPS: after 1 hour of 
exposure, only ADORA1 is slightly increased but returns to its original level at 4 hours, after 
four hours, while CCR7 is increased CCR2 and CXR4 are repressed. Our results for these 
genes obtained after 2 hours 30 of exposure are compatible and consistent with those 
described before (Sharif et al. 2007). In Table 6 are represented the 3 receptors whose 
expression varies significantly for CD patients. Why and how genes are regulated in the 
context of healthy individuals or with the disease and how they are connected to other 
receptors deregulated in CD patients, are questions difficult to be answered at this level of 
study. However, the large number of genes controlled by LPS in both healthy subjects and 
CD patients, compared to three genes differentially controlled, suggests that PBMC from the 
two populations have the capacity to respond very similarly to LPS activation, suggesting 
that CD patients PBMCs are only moderately disturbed in response to a bacterial infection. 
However, we can not exclude that one of the 3 receptors that differentiate two groups of 
individuals in response to bacterial stimuli, could control a signaling pathway involved, 
directly or indirectly, in CD. For example, disability and loss of immunological tolerance 
vis-à-vis certain species of commensal bacteria in the intestine is characteristic of CD 
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patients and are often put forward to explain the chronicity of the inflammatory state (Sartor 
2003). The expression profiles of GPCR in inflamed zones of Crohn patients clearly suggest a 
close relationship between the inflammatory process and the nervous system. Our results 
have shown unequivocally chemokine receptors (ADORA1, BLR1, CCR6, CCR7, CCR8, 
IL8RA, IL8RB) many neuropeptide receptors and neurotransmitter in the disease. 
Neuropeptide receptors and neurotransmitter occupy an essential place in the nervous 
system to ensure the function of the intestinal wall. The nervous system is complex: the 
autonomous nervous system consists of a network of nerve fibers connected to the plexus 
that connect the different layers of the wall and sympathetic and parasympathetic fibers that 
make synapses in small intramural ganglia. The autonomous nervous system ensures 
glandular secretion, vasodilation and vasoconstriction, and motility of smooth muscle fibers. 
The colon wall is also controlled by the vegetative nervous system under the control of the 
hypothalamic-adrenal-hypophysio-surrenal axis. It is through him that emotions, stress and 
fatigue affect the functioning of the digestive system (Taylor & Keely 2007). 
The presence of chemokine receptors, neuropeptides and neurotransmitters suggests a close 
relationship and communication between nerve cells, the intestinal lining cells and immune 
cells in the inflammatory zone. These links are illustrated by the endocrine cells, for 
example, the colonic epithelium that secrete polypeptide hormones and neurotransmitters 
such as gastrin, cholecystokinin (CCK), VIP (vasoactive intestinal peptide), substance P, 
bombesin and somatostatin and serotonin, which also act as neurotransmitters. If the effect 
of the ligands is relatively well documented in all functions related to the nervous system, 
transmission potential, secretion, muscle contractility, the role of receptors is more complex. 
The increase in receptors in the inflammatory tissue of CD is consistent with a general 
increase in neuronal signaling, described in the literature in terms of neuropeptides and 
neurotransmitters. At this stage of the study, interpretation of the increase in these receptors 
and their role in the inflammation is difficult without information on the characteristics of 
cells in which they are overexpressed. 
These increases can be linked to altered activity of nerve cells under the influence of 
inflammatory mediators or a nervous system response to restore tissue to a normal state. 
The histology of the intestinal mucosa, as we observed on our CD biopsies, must be 
accompanied by a remodeling of the enteric system so that it can perform its functions. It is 
a set of elements that are responsible for these changes: neuronal plasticity, all of these 
neuronal modulations, changes in morphology, the number and development of new 
dendrites for connective, but the emergence of new nerve cells (Geboes & Collins 1998). The 
increase of certain nerve cells may explain the increase in receptors. Enterochromaffin cells 
contain many neuroactive substances such as serotonin, bradykinin, tachykinin and 
prostaglandin that are released by multiple stimuli, mechanical, chemical and nervous. The 
release of serotonin, which has many roles (such as the increase in intestinal motility, 
vasoconstriction, synaptic transmission), is controlled at the level of enterochromaffin cells 
by receptors some of which have a stimulatory activity (HTR1, HTR2, MCR3) while others 
have an inhibitory activity (HTR3, type purinergic receptor P2Y, histamine, neurokinin, 
somatostatin). In these cells, two receptors HTR2 A and B increased in Crohn's disease, have 
a role rather amplifier of the disease. It would be the same level of sensory nerves that 
express a wide range of receptor on their surface. Neuronal activity is controlled mainly by 
receptor of natural substances such as VIP or substance P, but the activity can be altered by 
the presence of inflammatory products (serotonin, bradykinin, prostaglandin leukotriene, 
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ATP) and usually results in hyper excitability. Generally, treatment uses antagonists of these 
receptors (Hansen 2003). 
All nerve cells do not have the same contribution in the development of the disease. For 
example, in terms of motility disorders, due to alterations in signal transmission at synapses 
of the enteric nerves, it was shown that motility of the intestine is controlled by the 
adrenergic sympathetic fibers that decrease while the parasympathetic fibers stimulate the 
cholinergic (Smith & Smid 2005). Studies show that agents which promote parasympathetic 
activity also tend to reduce the severity of the disease, and conversely for sympathetic 
activity (Miceli & Jacobson 2003). It would be interesting to know the repertoire of these 
receptors in nerve cells and identify those that are deregulated in order to use agonists or 
antagonists to restore gut motility. 
Results reported here are encouraging nevertheless they remain preliminary. It will be 
necessary to analyze a larger number of samples, identify exactly the biopsy position in the 
colon and obtain relevant information on individuals before hoping to get molecular 
signatures of the different types of bowel diseases. In a therapeutic point of view, our results 
on the transcriptome of GPCRs from Crohn's disease biopsies offer a wide range of potential 
therapeutic targets, for functions as diverse as those related to the immune response, 
hormonal regulations, transfers of nervous information nerve, or blood clotting. 
5. Acknowledgment  
The study was supported by a grant from ACI 2002, MNRT, CNRS-INSERM-CEA, 
Pathologies-RCPG-Médicaments France. Nathalie Taquet was supported by a grant from 
FERRING laboratories (Gentilly, France) and Jean-Marie Reimund received a grant from 
UCB Laboratories, France. 
6. References 
Andres, P. G. & Friedman, L. S. (1999). Epidemiology and the natural course of 
inflammatory bowel disease. Gastroenterol Clin North Am, Vol.28  N°2 (Jun), pp. 
255-281  
Baker, P. E., Fahey, J. V. & Munck, A. (1981). Prostaglandin inhibition of T-cell proliferation 
is mediated at two levels. Cell Immunol, Vol.61  N°1 (Jun), pp. 52-61  
Baldassano, R. N. & Piccoli, D. A. (1999). Inflammatory bowel disease in pediatric and 
adolescent patients. Gastroenterol Clin North Am, Vol.28  N°2 (Jun), pp. 445-458  
Boldrick, J. C., Alizadeh, A. A., Diehn, M., Dudoit, S., Liu, C. L., Belcher, C. E., Botstein, D., 
Staudt, L. M., Brown, P. O. & Relman, D. A. (2002). Stereotyped and specific gene 
expression programs in human innate immune responses to bacteria. Proc Natl 
Acad Sci U S A, Vol.99  N°2 (Jan 22), pp. 972-977  
Burczynski, M. E., Peterson, R. L., Twine, N. C., Zuberek, K. A., Brodeur, B. J., Casciotti, L., 
Maganti, V., Reddy, P. S., Strahs, A., Immermann, F., Spinelli, W., Schwertschlag, 
U., Slager, A. M., Cotreau, M. M. & Dorner, A. J. (2006). Molecular classification of 
Crohn's disease and ulcerative colitis patients using transcriptional profiles in 
peripheral blood mononuclear cells. J Mol Diagn, Vol.8  N°1 (Feb), pp. 51-61  
Chomczynski, P. & Sacchi, N. (1987). Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, Vol.162  N°1 
(Apr), pp. 156-159  
www.intechopen.com
Inflammatory Bowel Disease G-Protein Coupled  
Receptors (GPCRs) Expression Profiling with Microfluidic Cards 85 
Dieckgraefe, B. K., Stenson, W. F., Korzenik, J. R., Swanson, P. E. & Harrington, C. A. (2000). 
Analysis of mucosal gene expression in inflammatory bowel disease by parallel 
oligonucleotide arrays. Physiol Genomics, Vol.4  N°1 (Nov 9), pp. 1-11  
Elson, C. O., Sartor, R. B., Tennyson, G. S. & Riddell, R. H. (1995). Experimental models of 
inflammatory bowel disease. Gastroenterology, Vol.109  N°4 (Oct), pp. 1344-1367  
Geboes, K. & Collins, S. (1998). Structural abnormalities of the nervous system in Crohn's 
disease and ulcerative colitis. Neurogastroenterol Motil, Vol.10  N°3 (Jun), pp. 189-
202  
Hansen, M. B. (2003). The enteric nervous system I: organisation and classification. 
Pharmacol Toxicol, Vol.92  N°3 (Mar), pp. 105-113  
Lawrance, I. C., Fiocchi, C. & Chakravarti, S. (2001). Ulcerative colitis and Crohn's disease: 
distinctive gene expression profiles and novel susceptibility candidate genes. Hum 
Mol Genet, Vol.10  N°5 (Mar 1), pp. 445-456  
Luther, S. A. & Cyster, J. G. (2001). Chemokines as regulators of T cell differentiation. Nat 
Immunol, Vol.2  N°2 (Feb), pp. 102-107  
Matsuura, T., West, G. A., Youngman, K. R., Klein, J. S. & Fiocchi, C. (1993). Immune 
activation genes in inflammatory bowel disease. Gastroenterology, Vol.104  N°2 
(Feb), pp. 448-458  
Miceli, P. C. & Jacobson, K. (2003). Cholinergic pathways modulate experimental 
dinitrobenzene sulfonic acid colitis in rats. Auton Neurosci, Vol.105  N°1 (Apr 30), 
pp. 16-24 1566-0702 (Print) 
Nau, G. J., Richmond, J. F., Schlesinger, A., Jennings, E. G., Lander, E. S. & Young, R. A. 
(2002). Human macrophage activation programs induced by bacterial pathogens. 
Proc Natl Acad Sci U S A, Vol.99  N°3 (Feb 5), pp. 1503-1508  
Onuffer, J. J. & Horuk, R. (2002). Chemokines, chemokine receptors and small-molecule 
antagonists: recent developments. Trends Pharmacol Sci, Vol.23  N°10 (Oct), pp. 459-
467  
Parker, L. C., Whyte, M. K., Vogel, S. N., Dower, S. K. & Sabroe, I. (2004). Toll-like receptor 
(TLR)2 and TLR4 agonists regulate CCR expression in human monocytic cells. J 
Immunol, Vol.172  N°8 (Apr 15), pp. 4977-4986  
Podolsky, D. K. (2002). Inflammatory bowel disease. N Engl J Med, Vol.347  N°6 (Aug 8), pp. 
417-429  
Rockett, J. C., Burczynski, M. E., Fornace, A. J., Herrmann, P. C., Krawetz, S. A. & Dix, D. J. 
(2004). Surrogate tissue analysis: monitoring toxicant exposure and health status of 
inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl 
Pharmacol, Vol.194  N°2 (Jan 15), pp. 189-199  
Sartor, R. B. (2003). Targeting enteric bacteria in treatment of inflammatory bowel diseases: 
why, how, and when. Curr Opin Gastroenterol, Vol.19  N°4 (Jul), pp. 358-365  
Satsangi, J., Parkes, M., Louis, E., Hashimoto, L., Kato, N., Welsh, K., Terwilliger, J. D., 
Lathrop, G. M., Bell, J. I. & Jewell, D. P. (1996). Two stage genome-wide search in 
inflammatory bowel disease provides evidence for susceptibility loci on 
chromosomes 3, 7 and 12. Nat Genet, Vol.14  N°2 (Oct), pp. 199-202  
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., 
Menzel, W., Granzow, M. & Ragg, T. (2006). The RIN: an RNA integrity number for 
assigning integrity values to RNA measurements. BMC Mol Biol, Vol.7   pp. 3 1471-
2199 (Electronic) 
www.intechopen.com
 
Crohn's Disease 86
Sharif, O., Bolshakov, V. N., Raines, S., Newham, P. & Perkins, N. D. (2007). Transcriptional 
profiling of the LPS induced NF-kappaB response in macrophages. BMC Immunol, 
Vol.8   pp. 1  
Sirover, M. A. (1999). New insights into an old protein: the functional diversity of 
mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta, 
Vol.1432  N°2 (Jul 13), pp. 159-184  
Smith, A. S. & Smid, S. D. (2005). Impaired capsaicin and neurokinin-evoked colonic 
motility in inflammatory bowel disease. J Gastroenterol Hepatol, Vol.20  N°5 (May), 
pp. 697-704  
Tatton, W. G., Chalmers-Redman, R. M., Elstner, M., Leesch, W., Jagodzinski, F. B., Stupak, 
D. P., Sugrue, M. M. & Tatton, N. A. (2000). Glyceraldehyde-3-phosphate 
dehydrogenase in neurodegeneration and apoptosis signaling. J Neural Transm 
Suppl N°60 pp. 77-100  
Taylor, C. T. & Keely, S. J. (2007). The autonomic nervous system and inflammatory bowel 
disease. Auton Neurosci, Vol.133  N°1 (Apr 30), pp. 104-114  
Thelen, M. (2001). Dancing to the tune of chemokines. Nat Immunol, Vol.2  N°2 (Feb), pp. 
129-134  
Warner, E. E. & Dieckgraefe, B. K. (2002). Application of genome-wide gene expression 
profiling by high-density DNA arrays to the treatment and study of inflammatory 
bowel disease. Inflamm Bowel Dis, Vol.8  N°2 (Mar), pp. 140-157  
Wurfel, M. M., Park, W. Y., Radella, F., Ruzinski, J., Sandstrom, A., Strout, J., Bumgarner, R. 
E. & Martin, T. R. (2005). Identification of high and low responders to 
lipopolysaccharide in normal subjects: an unbiased approach to identify 
modulators of innate immunity. J Immunol, Vol.175  N°4 (Aug 15), pp. 2570-2578  
www.intechopen.com
Crohn's Disease
Edited by Dr. Sami Karoui
ISBN 978-953-307-811-3
Hard cover, 210 pages
Publisher InTech
Published online 13, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In this book, several important points regarding Crohn's disease are discussed. In the first section, we focus on
etiopathogeny of Crohn's disease and the recent advances in our overall understanding of the disease -
specifically, the role of the gut epithelium, alterations of the epithelial crypts, and the roles of the different
cytokines in the pathophysiology of Crohn's disease. In the second section, a diagnosis of Crohn's disease is
discussed. Another particular area of focus is in the diagnosis of intestinal tuberculosis, and the role of
mycobacterium avium in Crohn's disease. In the third and final section, the management of Crohn's disease is
discussed, with a focus on recent evidence-based medicine recommendations.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Nathalie Taquet, Claude Philippe, Jean-Marie Reimund and Christian D. Muller (2012). Inflammatory Bowel
Disease G-Prote in Coupled Receptors (GPCRs) Expression Profiling with Microfluidic Cards, Crohn's Disease,
Dr. Sami Karoui (Ed.), ISBN: 978-953-307-811-3, InTech, Available from:
http://www.intechopen.com/books/crohn-s-disease/inflammatory-bowel-disease-g-prote-in-coupled-receptors-
gpcrs-expression-profiling-with-microfluidic
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
